Navigation Links
NDO Receives FDA 510(K) Clearance for Plicator II(TM)
Date:9/22/2007

Strengthens Position as the Global Leader in Endoscopic Anti-Reflux Surgery

MANSFIELD, Mass., Sept. 20 /PRNewswire/ -- NDO Surgical, Inc. (NDO) announced that the US Food and Drug Administration (FDA) cleared the Company's Plicator II(TM) multiple implant technology for immediate sale and distribution. Plicator II technology offers improved outcomes for harder-to-treat gastroesophageal reflux disease (GERD) patients.

"This clearance and the subsequent launch of next-generation Plicator(R) technology strengthen our global leadership position in endoscopic anti-reflux surgery," said Bernard Haffey, President and CEO of NDO. "More patients can now choose the Plicator procedure with confidence in its associated safety and efficacy."

FDA clearance of the new Plicator technique was based on agency review of a multi-center, forty patient clinical trial in which eighty percent (80%) of treated patients experienced superior GERD symptom control at 6 months post-treatment. Seventy percent (70%) of treated patients recorded 6-month GERD-HRQL (health-related quality of life) scores that were better than the scores recorded while patients were being treated for GERD with proton pump inhibitor (PPI) medications.

"Plicator technology is currently the best endoluminal GERD treatment on the market and occupies a critical place in our treatment algorithm," said Lee Swanstrom, MD, Program Director of Minimally Invasive Surgery at Legacy Health System in Portland, Oregon. "For selected reflux patients, Plicator affords excellent symptom relief and normalized acid exposure. I look forward to treating an even larger segment of my GERD patients by incorporating the Plicator II multiple implant technique into our practice."

In addition, the study demonstrated significantly reduced esophageal acid exposure, improved esophageal manometry and lowered esophagitis scores together with a markedly reduced dependency on GERD medications. Results achieved in this study represent an improvement over previously reported treatment outcomes using a single implant treatment technique with improved outcomes achieved in a more difficult to treat patient population.

About NDO Surgical

Based in Mansfield, Mass., NDO Surgical, Inc. (NDO) is a leader in flexible endoscopic technologies that enable surgical procedures through the body's natural openings. The company's first product, the Plicator, treats gastroesophageal reflux disease (GERD), a debilitating condition that affects 15M Americans. The Plicator is also the leading gastric closure device for Natural Orifice Translumenal Endoscopic Surgery (NOTES) research procedures. Investors include Versant Ventures, Polaris Ventures, and Menlo Ventures. Additional information is available at the Company's website at http://www.ndosurgical.com.


'/>"/>
SOURCE NDO Surgical, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Infant receives first bloodless liver transplant
2. British MPs Say Prostate Cancer Receives Low Priority in the NHS
3. Fifth US Patient Receives Artificial Heart
4. Northfield Labs Receives FDA Comments
5. Abbott Receives CE Mark Certification
6. Zactima Receives Fast Track Designation By The FDA
7. East London Receives World Class New Private Hospital Facility
8. Brinda Karat Receives Legal Notice over Ramdev Issue
9. Quake-Hit Pakistan Receives 30 Field Hospitals From Cuba
10. Medtronic’s Insulin Pump Receives Regulatory Approva
11. Aurobindo Receives Approval from USFDA for anti-AIDS drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ... communities in the greater Dallas, Miami, and Raleigh regions, is organizing an extended ... overcome a rare and deadly chromosome abnormality. , After struggling since birth with ...
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work to ... “patient engagement.” The patient is doing more than filling out a survey; in many ... is an increasing emphasis in health care and research on the importance of active ...
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's ... President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. ... 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming the role ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a ... utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the ... a CBD form that can be easily incorporated into liquid products, while reducing costs ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of ... ElderCounsel, a national organization of elder law and special needs planning attorneys. “Membership in ... It also provides a forum to network with elder law attorneys nationwide,” said Somekh. ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal ... Friday, November 3, 2017, beginning at 7:00 a.m. (CDT) ... a.m. (CDT) / 9:30 a.m. (EDT). In ... guidance for 2018, Hill-Rom executives will also highlight the ... long-range financial outlook through 2020. ...
(Date:9/27/2017)... 27, 2017  Commended for their devotion to personalized service, ... as number one in the South Florida Business Journal,s 50 ... 5000 yearly list, the national specialty pharmacy has found its ... will soon be honored by SFBJ as the 2017 ... Set to receive his award in October, Bardisa said ...
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
Breaking Medicine Technology: